About Innocoll

Innocoll is a biotherapeutics pharmaceutical company committed to improving the status quo and finding answers to unmet needs

About Us

XARACOLL®

Our lead investigational product is a drug-device surgical implant being developed for potential uses in addressing postsurgical pain

XARACOLL

Latest News

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant

15 Apr
Results of implant’s safety, efficacy and pharmacokinetics for use in various open soft-tissue surgeries expected in first quarter 2022 April...
Read More

Louis Pascarella Appointed Chief Executive Officer of Innocoll

12 Jan
Louis Pascarella has been named the company’s Chief Executive Officer and a member of Innocoll’s Board of Directors. Pascarella, who will retain his current role of President, succeeds Rich Fante, who is stepping down after a successful tenure as CEO and has agreed to serve as an adviser to Innocoll’s Board for at least the next year to ensure a smooth transition.
Read More

Innocoll Holdings Limited Appoints Richard Fante as Chief Executive Officer

5 Mar
ATHLONE, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Innocoll Holdings Limited (“Innocoll”), a specialty pharmaceutical company wholly owned by Gurnet Point Capital, announced...
Read More

Business Development Group
Unit 9, Block D
Monksland Business Park
Monksland
Athlone
Co. Roscommon
Ireland

Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: inquiries@innocoll.com

Innocoll Holdings Limited, a private company limited by shares, incorporated in Ireland having company number 544604 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland.

© 2020-2004 Innocoll. All rights reserved.
All Trademarks are owned by Innocoll Pharmaceuticals Limited